Statins: The new aspirin?

Cellular and Molecular Life Sciences

Volumn 59, Issue 11, 2002, Pages 1771-1786

  Veillard, N R ^a   Mach, Francois ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Atherosclerosis; Cholesterol; Inflammation; Pleiotropic effect; Statin

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; C REACTIVE PROTEIN; CERIVASTATIN; CHOLESTEROL; COMPACTIN; CYTOKINE; FLUINDOSTATIN; GAMMA INTERFERON; GUANINE NUCLEOTIDE BINDING PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MEVALONIC ACID; MEVINOLIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL PROLIFERATION; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; ENDOTHELIUM CELL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; IMMUNOMODULATION; INFLAMMATION; LIVER FUNCTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MOUSE; MULTICENTER STUDY; MYOPATHY; NONHUMAN; REVIEW; RHABDOMYOLYSIS; SLOW RELEASE FORMULATION; STROKE;

ADJUVANTS, IMMUNOLOGIC; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICHOLESTEREMIC AGENTS; APOPTOSIS; ARTERIOSCLEROSIS; ASPIRIN; ENDOTHELIUM; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION;

ANIMALIA;

EID: 0036867764     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00012505     Document Type: Review

References (188)

1. Navab M., Berliner J. A., Watson A. D., Hama S. Y., Territo M. C., Lusis A. J. et al. (1996) The Yin and Yang of oxidation in the development of the fatty streak: A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler. Thromb. Vasc. Biol. 16: 831-842
2. Glass C. K. and Witztum J. L. (2001) Atherosclerosis: The road ahead. Cell 104: 503-516
3. Libby P., Ridker P. M. and Maseri A. (2002) Inflammation and atherosclerosis. Circulation 105: 1135-1143
4. Rosamond W. D., Chambless L. E., Folsom A. R., Cooper L. S., Conwill D. E., Clegg L. et al. (1998) Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N. Engl. J. Med. 339: 861-867
5. Heart and Stroke Statistical Update (2001) American Heart Association, Dallas, Tex.
6. Post-Stroke Rehabilitation Guideline Panel No 16 (1995) Agency for Health Care Policy and Research, 95-0662
7. Bryan R. N., Wells S. W., Miller T. J., Elster A. D., Jungreis C. A., Poirier V. C. et al. (1997) Infarct like lesions in the brain: Prevalence and anatomic characteristics at MR imaging of the elderly - Data from the Cardiovascular Health Study. Radiology 202: 47-54
8. Spieker L. E., Hürlimann D., Ruschitzka F., Corti R., Enseleit E, Shaw S. et al. (in press) Mental stress induces prolonged endothelial dysfunction via endothelin-A receptors. Circulation 105
9. Macleod J., Davey Smith G., Heslop P., Metcalfe C., Carroll D. and Hart C. (2002) Psychological stress and cardiovascular disease: Empirical demonstration of bias in a prospective observational study of Scottish men. BMJ 324: 1247
10. Endo A. (1992) The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res. 33: 1569-1582
11. Kuroda M., Hazama-Shimada Y. and Endo A. (1977) Inhibition of sterol synthesis by citrinin in a cell-free system from rat liver and yeast. Biochim. Biophys. Acta 486: 254-259
12. Endo A., Tsujita Y., Kuroda M. and Tanzawa K. (1977) Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Eur. J. Biochem. 77: 31-36
13. Page C. P., Curtis M. J., Sutter M. C., Walter M. J. A. H. and Hoffman B. B. (1997). In: Integrated Pharmacology. pp 267-270, Mosby (ed).
14. Black D. M. (2002) A general assessment of the safety of HMG CoA reductase inhibitors (statins). Curr. Atheroscler. Rep. 4: 34-41
15. Corsini A., Bellosta S., Baetta R., Fumagalli R., Paoletti R. and Bernini F. (1999) New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther. 84: 413-428
16. Serajuddin A. T., Ranadive S. A. and Mahoney E. M. (1991) Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. J. Pharm. Sci. 80: 830-834
17. LaRosa J. C., He J. and Vupputuri S. (1999) Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials. JAMA 282: 2340-2346
18. Furberg C. D. (1999) Natural statins and stroke risk. Circulation 99: 185-188
19. Stein E., Plotkin D., Bays H., Davidson M., Dujovne C., Korenman S. et al. (2000) Effects of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia. Am. J. Cardiol. 86: 406-411
20. Jones P., Kafonek S., Laurora I. and Hunninghake D. (1998) Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am. J. Cardiol. 81: 582-587
21. Goldstein J. L. and Brown M. S. (1990) Regulation of the mevalonate pathway. Nature 343: 425-430
22. Rosenson R. S. and Tangney C. C. (1998) Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction. JAMA 279: 1643-1650
23. Bernini F., Didoni G., Bonfadini G., Bellosta S. and Fumagalli R. (1993) Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages. Atherosclerosis 104: 19-26
24. Bellosta S., Bernini F., Ferri N., Quarato P., Canavesi M., Arnaboldi L. et al. (1998) Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis, 137 (suppl): S101-S109
25. Glomset J. A., Gelb M. H. and Farnsworth C. C. (1990) Prenyl proteins in eukaryotic cells: A new type of membrane anchor, Trends Biochem. Sci. 15: 139-142
26. Maltese W. A. (1990) Posttranslational modification of proteins by isoprenoids in mammalian cells. FASEB J. 4: 3319-3328
27. Van Aelst L. and D'Souza-Schorey C. (1997) Rho GTPases and signaling networks. Genes Dev. 11: 2295-2322
28. Laufs U. and Liao J. K. (1998) Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J. Biol. Chem. 273: 24266-24271
29. Laufs U., La Fata V., Plutzky J. and Liao J. K. (1998) Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97: 1129-1135
30. Hall A. (1998) Rho GTPases and the actin cytoskeleton. Science 279: 509-514
31. Laufs U. and Liao J. K. (2000) Targeting Rho in cardiovascular disease. Circ. Res. 87: 526-528
32. Laufs U., Endres M., Stagliano N., Amin-Hanjani S., Chui D. S., Yang S. X. et al. (2000) Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J. Clin. Invest. 106: 15-24
33. Laufs U., Marra D., Node K. and Liao J. K. (1999) 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27 (Kip1). J. Biol. Chem 274: 21926-21931
34. Mundy G., Garrett R., Harris S., Chan J., Chen D., Rossini G. et al. (1999) Stimulation of bone formation in vitro and in rodents by statins. Science 286: 1946-1949
35. Singh R., Wang B., Shirvaikar A., Khan S., Kamat S., Schelling J. R. et al. (1999) The IL-1 receptor and Rho directly associate to drive cell activation in inflammation. J. Clin. Invest. 103: 156I-1570
36. Baetta R., Donetti E., Comparato C., Calore M., Rossi A., Teruzzi C. et al. (1997) Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells. Pharmacol. Res. 36: 115-121
37. Essig M., Nguyen G, Prie D., Escoubet B., Sraer J. D. and Friedlander G. (1998) 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells: Role of geranylgeranylation and Rho proteins. Circ. Res. 83: 683-690
38. Hernandez-Perera O., Perez-Sala D., Navarro-Antolin J., Sanchez-Pascuala R., Hernandez G., Diaz C. et al. (1998) Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J. Clin. Invest. 101: 2711-2719
39. Munro E., Patel M., Chan P., Betteridge L., Clunn G., Gallagher K. et al. (1994) Inhibition of human vascular smooth muscle cell proliferation by lovastatin: the role of isoprenoid intermediates of cholesterol synthesis. Eur. J. Clin. Invest. 24: 766-772
40. Martin G., Duez H., Blanquart C., Berezowski V., Poulain P., Fruchart J.C. et al. (2001) Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J. Clin. Invest. 107: 1423-1432
41. Inoue I., Itoh F., Aoyagi S., Tazawa S., Kusama H., Akahane M. et al. (2002) Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB. Biochem. Biophys. Res. Commun. 290: 131-139
42. Mangelsdorf D. J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K. et al. (1995) The nuclear receptor superfamily: The second decade. Cell 83: 835-839
43. Auboeuf D., Rieusset J., Fajas L., Vallier P., Frering V., Riou J. P. et al. (1997) Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: No alteration in adipose tissue of obese and NIDDM patients. Diabetes 46: 1319-1327
44. Granneman J., Skoff R. and Yang X. (1998) Member of the peroxisome proliferator-activated receptor family of transcription factors is differentially expressed by oligodendrocytes. J. Neurosci. Res. 51: 563-573
45. Braissant O. and Wahli W. (1998) Differential expression of peroxisome proliferator-activated receptor-PPAR-α, -β and -γ during rat embryonic development. Endocrinology 139: 2748-2754
46. Schoonjans K., Staels B. and Auwerx J. (1996) The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim. Biophys. Acta 1302: 93-109
47. Chinetti G., Fruchart J. C. and Staels B. (2001) Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors with functions in the vascular wall. Z. Kardiol. 90: 125-132
48. Duez H., Fruchart J. C. and Staels B. (2001) PPARS in inflammation, atherosclerosis and thrombosis. J. Cardiovasc. Risk 8: 187-194
49. Marx N., Kehrle B., Kohlhammer K., Grub M., Koenig W., Hombach V. et al. (2002) PPAR activators as antiinflammatory mediators in human T lymphocytes: Implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ. Res. 90: 703-710
50. Ricote M., Li A. C., Willson T. M., Kelly C. J. and Glass C. K. (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391: 79-82
51. Staels B., Koenig W., Habib A., Merval R., Lebret M., Torra I. P. et al. (1998) Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 393: 790-793
52. Delerive P., De Bosscher K., Besnard S., Vanden Berghe W., Peters J. M., Gonzalez F. J. et al. (1999) Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-I. J. Biol. Chem. 274: 32048-32054
53. Brand K., Page S., Rogler G., Bartsch A., Brandl R., Knuechel R. et al. (1996) Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J. Clin. Invest. 97: 1715-1722
54. Bustos C., Hernandez-Presa M. A., Ortego M., Tunon J., Orlega L., Perez F. et al. (1998) HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J. Am. Coll. Cardiol. 32: 2057-2064
55. Mach F. (2001) The role of chemokines in atherosclerosis. Curr. Atheroscler. Rep. 3: 243-251
56. Bourcier T., Sukhova G. and Libby P. (1997) The nuclear factor kappa-B signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis. J. Biol. Chem. 272: 15817-15824
57. Ueda A., Okuda K., Ohno S., Shirai A., Igarashi T., Matsunaga K. et al. (1994) NF-kappa B and Sp 1 regulate transcription of the human monocyte chemoattractant protein-1 gene. J. Immunol. 153: 2052-2063
58. Dain J. G., Fu E., Gorski J., Nicoletti J. and Scallen T. J. (1993) Biotransformation of fluvastatin sodium in humans. Drug Metab. Dispos. 21: 567-572
59. Christians U., Jacobsen W. and Floren L. C. (1998) Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are the statins mechanistically similar? Pharmacol. Ther. 80: 1-34
60. Quion J. A. and Jones P. H. (1994) Clinical pharmacokinetics of pravastatin. Clin. Pharmacokinet. 27: 94-103
61. Singhvi S. M., Pan H. Y., Morrison R. A. and Willard D. A. (1990) Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br. J. Clin. Pharmacol. 29: 239-243
62. McClellan K. J., Wiseman L. R. and McTavish D. (1998) Cerivastatin. Drugs. 55: 415-420
63. Lennernas H. and Fager G. (1997) Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors: Similarities and differences. Clin. Pharmacokinet. 32: 403-425
64. Becquemont L. (2000) Inhibiteurs de l'HMG-CoA réductase et interactions médicamenteuses. Lettre Pharmacol. 14: 64-68
65. Fischer V., Johanson L., Heitz F., Tullman R., Graham E., Baldeck J. P. et al. (1999) The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: Effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab. Dispos. 27: 410-416
66. Hodel C. (2002) Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol. Lett. 128: 159-168
67. Staffa J. A., Chang J. and Green L. (2002) Cerivastatin and reports of fatal rhabdomyolysis. N. Engl. J. Med. 346: 539-540
68. McQueen M. J. (1990) Cholestatic jaundice associated with lovastatin (Mevacor) therapy. Can. Med. Assoc. J. 142: 841-842
69. Theal R. M. and Scott K. (1996) Evaluating asymptomatic patients with abnormal liver function test results. Am. Fam. Physician 53: 2111-2119
70. Downs J. R., Clearfield M., Weis S., Whitney E., Shapiro D. R., Beere P. A. et al. (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279: 1615-1622
71. Pekkanen J., Linn S., Heiss G., Suchindran C. M., Leon A., Rifkind B. M. et al. (1990) Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N. Engl. J. Med. 322: 1700-1707
72. Pekkanen J., Tervahauta M., Nissinen A. and Karvonen M. J. (1993) Does the predictive value of baseline coronary risk factors change over a 30-year follow-up? Cardiology. 82: 181-190
73. The Expert Panel on Detection, Evalution, and Treatment of High Blood Cholesterol in Adults (1993) Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 269: 3015-3023
74. Grover S. A., Coupal L. and Hu X. P. (1995) Identifying adults at increased risk of coronary disease: How well do the current cholesterol guidelines work? JAMA 274: 801-806
75. Castelli W. P., Garrison R. J., Wilson P. W., Abbott R. D., Kalousdian S. and Kannel W. B. (1986) Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study JAMA 256: 2835-2838
76. Thompson S. G., Kienast J., Pyke S. D., Haverkate F. and Loo J. C. van de (1995) Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N. Engl. J. Med. 332: 635-641
77. Heinrich J., Balleisen L., Schulte H., Assmann G. and Loo J. van de (1994) Fibrinogen and factor VII in the prediction of coronary risk: Results from the PROCAM study in healthy men. Arterioscler. Thromb. 14: 54-59
78. Sweetnam P. M., Thomas H. F., Yarnell J. W., Beswick A. D., Baker I. A. and Elwood P. C. (1996) Fibrinogen, viscosity and the 10-year incidence of ischaemic heart disease. Eur. Heart. J. 17: 1814-1820
79. Scott H. D. and Laake K. (2001) Statins for the prevention of Alzheimer's disease. Cochrane Database Syst. Rev. 4
80. Fassbender K., Simons M., Bergmann C., Stroick M., Lutjohann D., Keller P. et al. (2001) Simvastatin strongly reduces leveis of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro nd in vivo. Proc. Natl. Acad. Sci. 98: 5856-5861
81. Corder E. H., Saunders A. M., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Small G. W. et al. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921-923
82. Hofman A., Ott A., Breteler M. M., Bots M. L., Slooter A. J., van Harskamp F. van et al. (1997) Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 349: 151-154
83. Bales K. R., Verina T., Dodel R. C., Du Y., Altstiel L., Bender M. et al. (1997) Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat. Genet. 17: 263-264
84. Refolo L. M., Malester B., LaFrancois J., Bryant-Thomas T., Wang R., Tint G. S. et al. (2000) Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 7: 321-331
85. Sparks D. L., Scheff S. W., Hunsaker J. C., 3rd Liu H., Landers T. and Gross D. R. (1994) Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp. Neurol. 126: 88-94
86. Simons M., Keller P., De Strooper B., Beyreuther K., Dotti C.G. and Simons K. (1998) Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. USA 95: 6460-6464
87. Wolozin B., Kellman W., Ruosseau P., Celesia G. G. and Siegel G. (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57: 1439-1443
88. Mach F., Sauty A., Iarossi A. S., Sukhova G. K., Neote K., Libby P. et al. (1999) Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J. Clin. Invest. 104: 1041-1050
89. Ignarro L. J. (1990) Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu. Rev. Pharmacol. Toxicol. 30: 535-560
90. Palmer R. M., Ferrige A. G. and Moncada S. (1987) Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327: 524-526
91. Radomski M. W., Palmer R. M. and Moncada S. (1990) An L-arginine/nitric oxide pathway present in human ptatelets regulates aggregation. Proc. Natl. Acad. Sci. USA 87: 5193-5197
92. Huang P. L., Huang Z., Mashimo H., Bloch K. D., Moskowitz M. A., Bevan J. A. et al. (1995) Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature. 377: 239-242
93. Furchgott R. F. and Zawadzki J. V. (1980) The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288: 373-376
94. Huang Z., Huang P. L., Ma J., Meng W., Ayata C., Fishman M. C. et al. (1996) Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine. J. Cereb. Blood Flow Metab. 16: 981-987
95. Huang Z., Huang P.L., Panahian N., Dalkara T., Fishman M.C. and Moskowitz M.A. (1994) Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science 265: 1883-1885
96. Morikawa E., Huang Z. and Moskowitz M. A. (1992) L-arginine decreases infarct size caused by middle cerebral arterial occlusion in SHR. Am. J. Physiol. 263: H1632-H1635
97. Zhang F. and Iadecola C. (1994) Reduction of focal cerebral ischemic damage by delayed treatment with nitric oxide donors. J. Cereb. Blood Flow Metab. 14: 574-580
98. Dalkara T., Morikawa E., Panahian N. and Moskowitz M. A. (1994) Blood flow-dependent functional recovery in a rat model of focal cerebral ischemia. Am. J. Physiol. 267: H678-H683
99. Laufs U., Fata V. L. and Liao J. K. (1997) Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J. Biol. Chem. 272: 31725-31729
100. Liao J. K., Zulueta J. J., Yu F. S., Peng H. B., Cote C. G. and Hassoun P. M. (1995) Regulation of bovine endothelial constitutive nitric oxide synthase by oxygen. J. Clin. Invest. 96: 2661-2666
101. Endres M., Laufs U., Huang Z., Nakamura T., Huang P., Moskowitz M. A. et al. (1998) Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. USA 95: 8880-8885
102. Stalker T. J., Lefer A. M. and Scalia R. (2001) A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: The role of mevalonic acid. Br. J. Pharmacol. 133: 406-412
103. Rikitake Y., Kawashima S., Takeshita S., Yamashita T. et al. (2001) Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 154: 87-96
104. Eto M., Kozai T., Cosentino F., Joch H. and Lüscher T. F. (2002) Statin prevents tissue factor expression in human endothelial cells: Role of Rho/Rho-kinase and Akt pathways. Circulation 105: 1756-1759
105. Bourcier T. and Libby P. (2000) HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler. Thromb. Vasc. Biol. 20: 556-562
106. Levin E. R. (1995) Endothelins. N. Engl. J. Med. 333: 356-363
107. Heeschen C., Hamm C.W., Laufs U., Snapinn S., Bohm M. and White H.D. (2002) Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 105: 1446-1452
108. Moreno P. R., Falk E., Palacios I. F., Newell J. B., Fuster V. and Fallon J. T. (1994) Macrophage infiltration in acute coronary syndromes: Implications for plaque rupture. Circulation 90: 775-778
109. Romano M., Mezzetti A., Marulli C., Ciabattoni G., Febo F., Di Ienno S. et al. (2000) Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: Role of nitric oxide. J. Invest. Med. 48: 183-189
110. Nakashima Y., Raines E. W., Plump A. S., Breslow J. L. and Ross R. (1998) Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse. Arterioscler. Thromb. Vasc. Biol. 18: 842-851
111. Shih P. T., Brennan M. L., Vora D. K., Territo M. C., Strahl D., Elices M. J. et al. (1999) Blocking very late antigen-4 integrin decreases leukocyte entry and fatty streak formation in mice fed an atherogenic diet. Circ. Res. 84: 345-351
112. Nie Q., Fan J., Haraoka S., Shimokama T. and Watanabe T. (1997) Inhibition of mononuclear cell recruitment in aortic intima by treatment with anti-ICAM-1 and anti-LFA-1 monoclonal antibodies in hypercholesterolemic rats: Implications of the ICAM-1 and LFA-1 pathway in atherogenesis. Lab. Invest. 77: 469-482
113. Weber C., Erl W., Weber K. S. and Weber P. C. (1997) HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J. Am. Coll. Cardiol. 30: 1212-1217
114. Weitz-Schmidt G., Welzenbach K., Brinkmann V., Kamata T., Kallen J., Bruns C. et al. (2001) Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. 7: 687-692
115. Rasmussen L. M., Hansen P. R., Nabipour M. T., Olesen P., Kristiansen M. T. and Ledet T. (2001) Diverse effects of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase on the expression of VCAM-1 and E-selectin in endothelial cells. Biochem. J. 360: 363-370
116. Romano M., Diomede L., Sironi M., Massimiliano L., Sottocorno M., Polentarutti N. et al. (2000) Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab. Invest. 80: 1095-1100
117. Pahan K., Sheikh F. G., Namboodiri A. M. and Singh I. (1997) Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J. Clin. Invest. 100: 2671-2679
118. Kothe H., Dalhoff K., Rupp J., Muller A., Kreuzer J., Maass M. et al. (2000) Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation 101: 1760-1763
119. Ikeda U. and Shimada K. (1999) Statins and monocytes. Lancet 353: 2070
120. Ikeda U., Hojo Y., Katsuki T. and Shimada K. (1999) Proco-agulant and proinflammatory activity in acute coronary syndromes. Cardiovasc. Res. 42: 823-824
121. Rudich S. M., Mongini P. K., Perez R. V. and Katznelson S. (1998) HMG-CoA reductase inhibitors pravastatin and simvastatin inhibit human B-lymphocyte activation. Transplant. Proc. 30: 992-995
122. Garlichs C. D., John S., Schmeisser A., Eskafi S., Stumpf C., Karl M. et al. (2001) Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation 104: 2395-2400
123. Vaughan C. J., Gotto A. M. Jr and Basson C. T. (2000) The evolving role of statins in the management of atherosclerosis. J. Am. Coll. Cardiol. 35: 1-10
124. Crisby M., Nordin-Fredriksson G., Shah P. K., Yano J., Zhu J. and Nilsson J. (2001) Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization. Circulation. 103: 926-933
125. Yoshida M., Sawada T., Ishii H., Gerszten R.E., Rosenzweig A., Gimbrone M. A. Jr et al. (2001) HMG-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: Involvement of Rho GTPase-dependent mechanism. Arterioscler. Thromb. Vasc. Biol. 21: 1165-1171
126. Wojciak-Stothard B., Williams L. and Ridley A. J. (1999) Monocyte adhesion and spreading on human endothelial cells is dependent on Rho-regulated receptor clustering. J. Cell. Biol. 145: 1293-1307
127. Liu L., Moesner P., Kovach N. L., Bailey R., Hamilton A. D., Sebti S. M. et al. (1999) Integrin-dependent leukocyte adhesion involves geranylgeranylated protein(s). J. Biol. Chem. 274: 33334-33340
128. Patel K. D., Zimmerman G. A., Prescott S. M., McEver R. P. and McIntyre T. M. (1991) Oxygen radicals induce human endothelial cells to express GMP-140 and bind neutrophils. J. Cell. Biol. 112: 749-759
129. Davenpeck K. L., Gauthier T. W. and Lefer A. M. (1994) Inhibition of endothelial-derived nitric oxide promotes P-selectin expression and actions in the rat microcirculation. Gastroenterology 107: 1050-1058
130. Baumann H. and Gauldie J. (1994) The acute phase response. Immunol. Today 15: 74-80
131. Ridker P. M., Rifai N., Clearfield M., Downs J. R., Weis S. E., Miles J. S. et al. (2001) Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N. Engl. J. Med. 344: 1959-1965
132. Liuzzo G., Biasucci L. M., Gallimore J. R., Grillo R. L., Rebuzzi A. G., Pepys M. B. et al. (1994) The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N. Engl. J. Med. 331: 417-424
133. Ridker P. M., Hennekens C. H., Buring J. E. and Rifai N. (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342: 836-843
134. Sacks F. M., Pfeffer M. A., Moye L. A., Rouleau J. L., Rutherford J. D., Cole T. G. et al. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 335: 1001-1009
135. Ridker P M., Rifai N. and Lowenthal S. P. (2001) Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 103: 1191-1193
136. Musial J., Undas A., Gajewski P., Jankowski M., Sydor W. and Szczeklik A. (2001) Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int. J. Cardiol. 77: 247-253
137. Ridker P. M., Rifai N., Pfeffer M. A., Sacks F. M., Moye L. A., Goldman S., Flaker G. C. et al. (1998) Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 98: 839-844
138. Wang X., Li X., Yue T. L. and Ohlstein E. H. (2000) Expression of monocyte chemotactic protein-3 mRNA in rat vascular smooth muscle cells and in carotid artery after balloon angioplasty. Biochim. Biophys. Acta 1500: 41-48
139. Hayes I. M., Jordan N. J., Towers S., Smith G., Paterson J.R., Earnshaw J. J., Roach A. G., Westwick J. et al. (1998) Human vascular smooth muscle cells express receptors for CC chemokines. Arterioscler. Thromb. Vasc. Biol. 18: 397-403
140. Raiteri M., Arnaboldi L., McGeady P., Gelb M.H., Verri D., Tagliabue C. et al. (1997) Pharmacological control of the mevalonate pathway: Effect on arterial smooth muscle cell proliferation. J. Pharmacol. Exp. Ther. 281: 1144-1153
141. Hidaka Y., Eda T., Yonemoto M. and Kamei T. (1992) Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733). Atherosclerosis 95: 87-94
142. Mulder H. J., Bal E. T., Jukema J. W., Zwinderman A. H., Schalij M. J., Boven A. J. van et al. (2000) Pravastatin reduces restenosis two years after percutaneous transluminal coronary angioplasty (REGRESS trial). Am. J. Cardiol. 86: 742-746
143. Walter D. H., Schachinger V, Elsner M., Mach S., Auch-Schwelk W. and Zeiher A. M. (2000) Effect of statin therapy on restenosis after coronary stent implantation. Am. J. Cardiol. 85: 962-968
144. Serruys P. W., de Feyter P. de, Macaya C., Kokott N., Puel J., Vrolix M. et al. (2002) Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial. JAMA 287: 3215-322
145. Weinberg R. A. (1995) The retinoblastoma protein and cell cycle control. Cell 81: 323-330
146. Hirai A., Nakamura S., Noguchi Y., Yasuda T., Kitagawa M., Tatsuno I. et al. (1997) Geranylgeranylated rho small GT-Pase(s) are essential for the degradation of p27Kip 1 and facilitate the progression from G1 to S phase in growth-stimulated rat FRTL-5 cells. J. Biol. Chem. 272: 13-16
147. Rogler G., Lackner K. J. and Schmitz G. (1995) Effects of fluvastatin on growth of porcine and human vascular smooth muscle cells in vitro. Am. J. Cardiol. 76: 114A-116A
148. Soma M. R., Donetti E., Parolini C., Mazzini G., Ferrari C., Fumagalli R. et al. (1993) HMG CoA reductase inhibitors: In vivo effects on carotid intimal thickening in normocholesterolemic rabbits. Arterioscler. Thromb. 13: 571-578
149. Stark W. W. Jr, Blaskovich M. A., Johnson B. A., Qian Y., Vasudevan A., Pitt B. et al. (1998) Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells. Am. J. Physiol. 275: L55-L63
150. Rembold C. (1996) Could atherosclerosis originate from defective smooth muscle cell death (apoptosis)? Perspect. Biol. Med. 39: 405-408
151. Bochaton-Piallat M. L., Gabbiani F., Redard M., Desmouliere A. and Gabbiani G. (1995) Apoptosis participates in cellularity regulation during rat aortic intimal thickening. Am. J. Pathol. 146: 1059-1064
152. Guijarro C., Blanco-Colio L. M., Ortego M., Alonso C., Ortiz A., Plaza J. J. et al. (1998) 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ. Res. 83: 490-500
153. Li X., Liu L., Tupper J. C., Bannerman D. D., Winn R. K., Sebti S. M. et al. (2002) Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells. J. Biol. Chem. 277: 15309-15316
154. Geng Y. J., Henderson L. E., Levesque E. B., Muszynski M. and Libby P. (1997) Fas is expressed in human atherosclerotic intima and promotes apoptosis of cytokine-primed human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 17: 2200-2208
155. Maciejewski J., Selleri C., Anderson S. and Young N. S. (1995) Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood 85: 3183-3190
156. Martinez-Gonzalez J., Vinals M., Vidal F., Llorente-Cortes V. and Badimon L. (1997) Mevalonate deprivation impairs IGF-I/insulin signaling in human vascular smooth muscle cells. Atherosclerosis 135: 213-223
157. Ross R. (1993) The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362: 801-809
158. Davies M. J., Richardson P. D., Woolf N., Katz D. R. and Mann J. (1993) Risk of thrombosis in human atherosclerotic plaques: Role of extracellular lipid, macrophage, and smooth muscle cell content. Br. Heart J. 69: 377-381
159. Burleigh M. C., Briggs A. D., Lendon C. L., Davies M. J., Born G. V. and Richardson P. D. (1992) Collagen types I and III, collagen content, GAGs and mechanical strength of human atherosclerotic plaque caps: Span-wise variations. Atherosclerosis 96: 71-81
160. Bennett M. R. (1999) Apoptosis of vascular smooth muscle cells in vascular remodelling and atherosclerotic plaque rupture. Cardiovasc. Res. 41: 361-368
161. Fuster V., Stein B., Ambrose J. A., Badimon L., Badimon J. J. and Chesebro J. H. (1990) Atherosclerotic plaque rupture and thrombosis: Evolving concepts. Circulation 82: 1147-1159
162. Takemoto M. and Liao J. K. (2001) Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler. Thromb. Vasc. Biol. 21: 1712-1719
163. Aikawa M., Rabkin E., Voglic S. J., Shing H., Nagai R., Schoen F. J. et al. (1998) Lipid lowering promotes accumulation of mature smooth muscle cells expressing smooth muscle myosin heavy chain isoforms in rabbit atheroma. Circ. Res. 83: 1015-1026
164. Bellosta S., Via D., Canavesi M., Pfister P., Fumagalli R., Paoletti R. et al. (1998) HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler. Thromb. Vasc. Biol. 18: 1671-1678
165. Fukumoto Y., Libby P., Rabkin E., Hill C. C., Enomoto M., Hirouchi Y. et al. (2001) Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation 103: 993-999
166. Aikawa M., Rabkin E., Sugiyama S., Voglic S. J., Fukumoto Y., Furukawa Y. et al. (2001) An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 103: 276-283
167. Wong B., Lumma W. C., Smith A. M., Sisko J. T., Wright S. D. and Cai T. Q. (2001) Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation. J. Leukoc. Biol. 69: 959-962
168. Chase A. J., Bond M., Crook M. F. and Newby A. C. (2002) Role of nuclear factor-kappaB activation in metalloproteinase-1, -3, and -9 secretion by human macrophages in vitro and rabbit foam cells produced in vivo. Arterioscler. Thromb. Vasc. Biol. 22: 765-771
169. Kobashigawa J. A., Katznelson S., Laks H., Johnson J. A., Yeatman L., Wang X. M. et al. (1995) Effect of pravastatin on outcomes after cardiac transplantation. N. Engl. J. Med. 333: 621-627
170. Wenke K., Meiser B., Thiery J., Nagel D., Scheidt W. von, Steinbeck G. et al. (1997) Simvastatin reduces graft vessel disease and mortality after heart transplantation: A four-year randomized trial. Circulation 96: 1398-1402
171. Reith W. and Mach B. (2001)The bare lymphocyte syndrome and the regulation of MHC expression. Annu. Rev. Immunol. 19: 331-373
172. Steimle V., Otten L. A., Zufferey M. and Mach B. (1993) Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 75: 135-146
173. Steimle V., Siegrist C. A., Mottet A., Lisowska-Grospierre B. and Mach B. (1994) Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 265: 106-109
174. Kwak B., Mulhaupt F., Veillard N., Pelli G. and Mach F. (2001) The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells. Swiss Med. Wkly 131: 41-46
175. Kwak B., Mulhaupt F., Myit S. and Mach F. (2000) Statins as a newly recognized type of immunomodulator. Nat. Med. 6: 1399-1402
176. Kwak B. R., Myit S., Mulhaupt F., Veillard N., Rufer N., Roosnek E. et al. (2002) PPARgamma but not PPARalpha ligands are potent repressors of major histocompatibility complex class II induction in atheroma-associated cells. Circ. Res. 90: 356-362
177. Sadeghi M. M., Tiglio A., Sadigh K., O'Donnell L., Collinge M., Pardi R. et al. (2001) Inhibition of interferon-gamma-mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors. Transplantation 71: 1262-1268
178. Kobashigawa J. A. (2001) Statins as immunosuppressive agents. Liver Transpl. 7: 559-561
179. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Smdy Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339: 1349-1357
180. The Scandinavian Simvastatin Survival Study (4S) (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 344: 1383-1389
181. Jukema J. W., Bruschke A. V., Boven A. J. van, Reiber J. H., Bal E. T., Zwinderman A. H. et al. (1995) Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 91: 2528-2540
182. Herd J. A., Ballantyne C. M., Farmer J. A., Ferguson J. J. 3rd, Jones P. H., West M. S. et al. (1997) Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am. J. Cardiol. 80: 278-286
183. Brown B. G., Zhao X. Q., Sacco D. E. and Albers J. J. (1993) Lipid lowering and plaque regression: New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 87: 1781-1791
184. Riegger G., Abletshauser C., Ludwig M., Schwandt P., Widimsky J., Weidinger G. et al. (1999) The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Atherosclerosis 144: 263-270
185. Shepherd J. (1995) Fibrates and statins in the treatment of hyperlipidaemia: An appraisal of their efficacy and safety. Eur. Heart. J. 16: 5-13
186. Heart Protection Study Collaborative Group. (2002) MRC/ BHF Heart Protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomized placebo-controlled trial. Lancet. 360: 7-22
187. Lescol Intervention Prevention Study (LIPS) investigators. (2002) Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention. JAMA. 287: 3215-3222
188. Athyros V. G., Papageorgiou A. A., Mercouris B. R., Athyrou V. V., Symeonidis A. N., Basayannis E. O. and Demitriadis D. S. (2002) Treatment with atorvastatin to the national cholesterol educational program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr. Med. Res. Opin. 18: 220-228